Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IMMUCELL CORP /DE/ (ICCC)

ImmuCell Q2 2026 Product Sales Rise 11.5% to $7.2 Million on Preliminary Results

Positive Impact 3 of 5 earnings Written later

ImmuCell Corporation reported preliminary, unaudited product sales of $7.2 million for the quarter ended June 30, 2026, up 11.5% from $6.4 million a year earlier, with domestic sales up 27.7% and international sales down 38.9%. Sales for the six months ended June 30, 2026 were $17.5 million, up 20.9%. The figures are unaudited and do not include profit or guidance, and the company will discuss complete results on August 14, 2026.

Key points

  • Q2 2026 total product sales were $7.2 million, up 11.5% from $6.4 million in Q2 2025.
  • Domestic sales rose 27.7% to $6.2 million, while international sales fell $0.6 million, or 38.9%, to $1.0 million.
  • Six-month sales were $17.5 million, up 20.9% from $14.5 million in the first half of 2025.
  • Management will discuss complete results on a conference call on Friday, August 14, 2026 at 9:00 AM ET.

The filing

CompanyIMMUCELL CORP /DE/ (ICCC)
Form8-K, current report
Filed with the SECJul 9, 2026, 4:08 PM ET
Accession number0001437749-26-023199

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.